The ReCySOHT study is a multicenter, retrospective, observational case-control study on the risk factors for developing a ganciclovir-resistant/refractory (GCV-RR) cytomegalovirus infection in patients receiving solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT). Aims of the study are to investigate the incidence of and risk factors for GCV-RR CMV infection in SOT recipients and HSCT patients in order to design further studies aimed at preventing and improving the patient management of GCV-RR CMV infections.
All adult (≥ 18 years) patients who underwent SOT or HSCT developing CMV-infection treated with GC/VGC
Ability to understand the purpose of the study and provide signed and dated informed consent
Lack of clinical and/or laboratory data regarding the type of CMV event
Lack of the serological mismatch at transplantation
Lack of the type of SOT or HSCT
Lack of the patient and graft outcome at 30, 60 or 90 days after CMV event diagnosis